Stocks · News reference

8-K filing — Scienture Holdings, Inc. (SCNX)

Aug 20, 2026, 8:05 PMSEC EDGAR

Filed: 2026-08-20 AccNo: 0001493152-26-039474 Size: 344 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SCNX

Source: edgar
Observed: Aug 20, 2026, 8:05 PM
Checked: Aug 20, 2026, 8:05 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 14, 2026, 12:23 PMBenzinga Newsdesk
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 85.42 percent increase over losses of $(0.48) per share
Read original at benzinga
SCNX
BenzingaAug 12, 2026, 11:46 AMVandana Singh
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
Scienture launches Rezenopy, a 10 mg naloxone nasal spray for opioid overdoses, fulfilling initial U.S. wholesale orders.
Read original at benzinga
SCNX
BenzingaAug 12, 2026, 11:45 AMBenzinga Newsdesk
EXCLUSIVE: Scienture Commences Commercial Launch and Fulfillment of Initial Rezenopy Orders; Targets Execution Through End of 2026 By Expanding Payer Coverage, Product Access, and Institutional Adoption
Read original at benzinga
SCNX

8-K filing — Scienture Holdings, Inc. (SCNX)

Connected markets

Related headlines

Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

EXCLUSIVE: Scienture Commences Commercial Launch and Fulfillment of Initial Rezenopy Orders; Targets Execution Through End of 2026 By Expanding Payer Coverage, Product Access, and Institutional Adoption